Abstract: This invention describes pyruvate and related ?-ketocarboxylates as novel adjuvants in the treatment of acute post-tooth-whitening pain and sensitivity; the key feature is the cytoprotective efficacy of pyruvate on oral soft tissue, especially after topical application of high and therefore cytotoxic concentrations of H2O2, currently used in tooth whitening procedures.

Abstract: The present disclosure provides personal care compositions comprising a surfactant system that includes an anionic surfactant, a zwitterionic or amphoteric surfactant and optionally a non-ionic surfactant; a preservative system; a pH modifier; optionally a moisturizer or a skin conditioner or both a moisturizer and a skin conditioner; and a viscosity adjusting system, wherein the viscosity adjusting system comprises glyceryl oleate and at least one additional viscosity adjusting agent. Use of the viscosity adjusting system can achieve viscosity levels that would otherwise not be possible by either agent alone, and allows for higher maximum viscosity levels while at the same time providing an emolliency to the formulation.

Abstract: Provided is a composition for controlling hair shape, which affords a superior feeling of hair touch (softness, smoothness, gathering property, gloss etc.), an effect of suppressing damage to the hair, forming a desired wave shape and the like, and sustaining the shape of the hair. A hair shape control assisting agent containing component (A): a compound represented by the formula (1) wherein each symbol is described in the SPECIFICATION, or a salt thereof.

Abstract: The present invention relates to a cosmetic composition for coating keratin fibres, comprising: —an aqueous phase, —a surfactant system present at a total content of greater than or equal to 15% by weight relative to the total weight of the composition, said surfactant system comprising: i) at least one non-ionic surfactant with an HLB value at 25° C. of less than 8, and ii) at least one anionic surfactant with an HLB value at 25° C. of greater than or equal to 8, chosen from acyl glutamic acids and salts thereof, together forming a lamellar phase L?, and —at least one lamellar filler. The present invention also relates to a process for coating keratin fibres.

Abstract: A method for reducing skin staining during the coloring of hair includes the following steps in the indicated sequence: A1) applying a coloring agent (F) to the hair, A2) allowing the coloring agent (F) to act for a time period from 30 seconds to 45 minutes, B1) applying an undiluted cleaning agent (R) to skin areas that can come into contact with the coloring agent (F) when the latter is washed out, C1) jointly washing out the coloring agent (F) and cleaning agent (R), wherein the coloring agent (F) includes at least one oxidation dye precursor and/or at least one direct dye and the cleaning agent (R) includes at least one anionic surfactant. A multicomponent packaging unit includes the coloring agent (F) and the cleaning agent (R).

Abstract: The present invention relates to a composition containing a material for regulating the expression of ABH antigens and, more specifically, to a composition capable of: controlling sebum production and alleviating skin trouble by regulating the expression of ABH antigens; preventing skin pore enlargement by providing antioxidant effects; and defending against skin irritation production.

Abstract: A method for treating hair loss in mammals uses compositions containing 2-decarboxy-2-phosphinico prostaglandin derivatives. The compositions can be applied topically to the skin. The compositions can arrest hair loss, reverse hair loss, and promote hair growth. Compositions containing 2-decarboxy-2-phosphinico prostaglandin derivatives can also be used to lower intraocular pressure and treat bone disorders.

Abstract: An isolated peptide for stimulating melanogenesis in a mammal subject is provided. The isolated peptide consisting of an amino acid sequence of FKCRRWQWRMK KLGAPSI (SEQ ID NO: 1). Also provided are methods and compositions for stimulating melanogenesis in a mammal subject.

Abstract: The present invention generally relates to compositions and methods for transdermal delivery, and treatment of hair related conditions. The compositions can be used in a variety of applications, including causing or promoting hair growth and/or hair pigmentation. In some cases, the composition may include nitric oxide and/or peptides. The nitric oxide and/or peptide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide, peptides, or both. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin, e.g., onto the scalp, or other suitable portion of the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like.

Abstract: An isolated peptide for inhibiting melanogenesis in a mammal subject is provided. The isolated peptide consisting of an amino acid sequence of SSASTTED (SEQ ID NO: 1). Also provided are methods and compositions for inhibiting melanogenesis in a mammal subject.

Abstract: The present invention relates to a composition for promoting hair growth or preventing hair loss and, specifically, to a composition, which has excellent stability for skin and no side effects, promotes hair growth, prevents hair loss through the delay of hair loss, and has an excellent hair growth effect.

Abstract: A starting (raw) material, for cosmetics, comprising a core corona type microgel dispersion obtained by radical polymerization of a specific polyethylene oxide macromonomer, a specific hydrophobic monomer, and a specific cross-linking monomer under specific conditions. The purpose of the present invention is to provide the raw material for cosmetics, with which the cosmetic having a high stability provides a good feeling in use and does not cause skin irritation, can be easily produced.

Abstract: The present invention is directed towards a composition, especially a cosmetic composition, in particular for coating keratin fibres such as the eyelashes, comprising: —at least one aqueous phase gelled with at least one synthetic polymeric hydrophilic gelling agent; and —at least one oily phase gelled with at least one lipophilic gelling agent chosen from meltable compounds, said oily phase also comprising at least one volatile oil; said phases forming therein a macroscopically homogeneous mixture, said composition comprising less than 10% by weight of non-volatile oil(s), relative to the total weight of the composition, said composition comprising from 10% to 70% by weight of volatile oil(s), relative to the total weight of the composition, said composition comprising a water content at least equal to 15% by weight relative to the total weight of the composition.

Abstract: The present disclosure pertains to compositions that include a linear polyether polymer, methods involving the application of such compounds to hair, methods for making hair conditioners using such compounds, and uses of compositions containing such compounds for conditioning of hair for increasing softness. The linear polyether polymer has a weight average less than 5000 and terminates with —N—(—CH2-CH(OH)—CH2-CI)2.

Abstract: The present invention relates to oral compositions for identifying plaque comprising a dental disclosing agent composition for revealing the presence of dental plaque in a person's mouth including natural colorants derived from purple carrot.

Abstract: An illuminating complex for enhancing beauty includes at least one of yangu seed oil, baobab seed oil, mafura butter (trichilia oil), dipotassium glycyrrhizinate, alpha-arbutin, and a structure forming agent. A pore refining complex includes at least one of kalahari melon seed oil, grapeseed oil, rooibos tea, an extract blend of at least one of witch hazel, white willow bark, acacia senegal, papaya seed, and lemongrass, and a structure forming agent. The structure forming agent preferably comprises at least one of an emulsification, an encapsulation, and liposomes.

Abstract: The present disclosure relates to a composition including an extract from an Acidithiobacillus bacteria or a yeast extracted after exposure of the bacteria to UV radiation. The disclosure further relates to a method of preparing a UV-blocking composition by exposing a culture of Acidithiobacillus or yeast to UV radiation and extracting UV-blocking cellular material produced in response to the UV radiation from the Acidithiobacillus or yeast. The disclosure further relates to a method of protecting an item from UV radiation damage by extracting UV-blocking cellular material from Acidithiobacillus or yeast exposed to UV radiation and covering the item with the UV-blocking cellular material. The disclosure further relates to a UV-resistant yeast cell and a UV-resistant bacterial cell.

Abstract: The Invention relates to an oromucosal film preparation. According to the invention, said oromucosal film preparation comprises an active-ingredient containing surface area (3) and an active-ingredient free surface area (4). Said surface area (4) which is free of active-ingredients can be used as an application aid for the safe and simple application of the film preparation.

Abstract: An orally administered dosage form that facilitates delivery of an agent locally in the buccal cavity for a sustained period of time includes mucoadhesive particles that are made of at least a mucoadhesive material combined with the agent, and which are dispersed in a disintegrating film. The dosage form is capable of delivering an agent to a patient at the desired oral mucosa site over an extended period of time while reducing patient discomfort or annoyance associated with conventional sustained release mucoadhesive films that must reside on the oral mucosa during the period of sustained release.

Abstract: The present invention provides a transdermal preparation excellent in transdermal absorbability using various active ingredients by virtue of a transdermal absorption enhancement aid or a transdermal absorption enhancer comprising an equimolar salt of a) a basic functional group-containing compound having a molecular weight of from 50 to 120 and a melting point of from 50 to 350° C., and b) an acidic functional group-containing compound having a Log P of ?4 to 7.3.

Abstract: Compositions, devices and methods employing therapeutic concentrations of a triptan for treatment of migraine are described. Also described are methods and apparatuses for delivery of zolmitriptan for achieving a Tmax as quick as 2 minutes and not later than 30 minutes in the majority of subjects.

Abstract: A composition and method are disclosed for treating orgasmic disorder in a female subject. The composition is a topical medicament containing tadalafil, menthol, and 1-arginine. The composition typically further comprises an extended release mucoadhesive polymer, and is used for topical application to the clitoris and genital tissues of a human female suffering from orgasmic disorder, which includes difficulty achieving orgasm and anorgasmia. Topical application of the inventive composition to the clitoral mucous membranes and other female genital tissues affects vasodilation and clitoral erection tier an extended period of time and compensates for low testosterone levels in a female subject.

Abstract: The disclosure relates to multilayer polymeric matrix based medical devices. In one example, a device comprises an inner first polymeric matrix and an outer second polymeric matrix. The addition of second polymeric matrix modifies bulk properties of each matrix thus resulting in a device where specific bulk properties are incorporated. The disclosure also relates to methods of manufacturing various embodiments of medical devices and their uses.

Abstract: This invention provides a process for preparing an inhalable dry powder pharmaceutical formulation comprising the step of heating a sealed wrapper containing a desiccant and an inhaler or a capsule, the inhaler or capsule further containing a dry powder formulation comprising an inhalable active pharmaceutical ingredient and a carrier, wherein the wrapper forms a barrier to the ingress of moisture and wherein heating the sealed wrapper and its contents is performed at a temperature of 30-50° C.

Abstract: The present invention relates to a liquid pharmaceutical composition suitable for administration by inhalation which comprises a diluent and a suspension of particles of 9,10-dimethoxy-2-(2,4,6-trimethylphenylimino)-3-(N-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one (RPL554) or a pharmaceutically acceptable salt thereof. Also described is a liquid pharmaceutical composition according to the invention for use in the treatment of the human or animal body.

Abstract: A flavored water composition for pets is disclosed. The disclosed flavored water composition for pets includes water and an oil-based nutrient.

Abstract: The present invention is directed to an aqueous gel composition containing a local anesthetic, a lubricating agent, and a preservative and methods of treating vaginal pain, such as dyspareunia by topically administering said composition.

Abstract: The present invention is directed to an aqueous gel composition containing a local anesthetic, a lubricating agent, and a preservative and methods of treating vulvovaginal pain, such as dyspareunia by topically administering said composition.

Abstract: The present invention provides liposomes loaded with chelating agents, pharmaceutical formulations including these liposomes and methods of making chelating agent liposomes. Because the chelating agents are loaded in the liposome with high efficiencies, the liposomes are of use in treatment of metal ion overload in subjects. The liposomes can also contain essential trace metals to compensate for the off target effect of removal of endogenous non-target trace metals by administration of the chelator. The liposomes can include two or more different chelating agents of different structures and affinities for metal ions.

Abstract: Provided herein are compositions for treating acute, chronic, or post-operative pain in a subject, said compositions comprising a Nav1.7 selective inhibitor and a biodegradable carrier, wherein the agent is incorporated within the biodegradable carrier. Methods of treating pain in a subject and kits for producing compositions for treating acute, chronic or post-operative pain in a subject are also disclosed herein.

Abstract: Many active pharmaceutical ingredients are not directly compressible, therefore addition of pharmaceutical excipients is necessary. Fillers are essential pharmaceutical excipients, among which sugars are commonly employed, especially lactose. It is required that such substances have good flowability and compressibility. The present invention enables a simple and industry applicable production of particles of spherically agglomerated lactose that have suitable flow properties, excellent compression characteristics and reduce or prevent occurrence of segregation in mixture for production of solid dosage forms. They are porous spherical agglomerates. Particles of spherically agglomerated lactose comprise prism-like primary particles that are radially arranged and form a bigger agglomerate structure. Particles of spherically agglomerated lactose have suitable size, are highly breakable, have relatively high specific surface area and enable production of tablets with high tensile strength.

Abstract: A solid administration form, protected from parenteral abuse and containing at least one viscosity-increasing agent in addition to one or more active substances that have parenteral abuse potential. The agent forms, when a necessary minimum amount of an aqueous liquid is added, on the basis of an extract obtained from the administration form, a preferably injectable gel that remains visually distinct when introduced into another quantity of an aqueous liquid.

Abstract: A package for delivering a single-dose product includes a softgel capsule which is comprised of at least one gelling agent selected from protein-based gelling agents and polysaccharide-based gelling agents. The capsule shell includes one or more areas of reduced thickness that are preferentially ruptured by exertion of a compressive force on the softgel capsule to create an opening in the capsule shell through which the fill composition can be delivered by spraying or squeezing. A method for manufacturing the softgel capsule having one or more areas of reduced shell thickness is also described.

Abstract: Novel delivery systems for highly hygroscopic active materials is disclosed. The delivery system comprising a hard capsule filled with a liquid composition consisting of a hygroscopic active material dispersed in a non-aqueous carrier. The carrier comprising, or consisting of, one or more lipophilic lipid substances and one or more rheology modifiers.

Abstract: A matrix formulation for a soft chewable capsule is provided which includes a gel-forming composition, a plasticizer, a polymer modifier, and water. The polymer modifier may be a carboxylic acid or other organic compound that alters the physical and/or chemical properties of the capsule formulation. A chewable soft capsule is also provided, having enhanced organo-leptic and processing properties. An active material may be delivered to a user using this dosage form. A method of forming the chewable soft capsule is also provided.

Abstract: A system for delivery of a therapeutic agent to a site in mucosal tissue is provided. The system includes a porous, mucoadhesive polymeric matrix having a first and a second opposed surfaces. The matrix is formed by a composition including chitosan, a hydration promoter, a microparticle adhesion inhibitor, and a microparticle aggregation inhibitor. A plurality of microparticles are embedded within the matrix. The microparticles contain a therapeutic agent and have a coating around the therapeutic agent. The first surface of the matrix is configured to be attached to the site in the mucosal tissue and the matrix is configured to provide controlled release of the microparticles through the first surface. The coating of the microparticles includes chitosan so as to provide controlled release of the agent from the microparticles.

Abstract: Covalently modified alginate polymers, possessing enhanced biocompatibility and tailored physiochemical properties, as well as methods of making and use thereof, are disclosed herein. The covalently modified alginates are useful as a matrix for the encapsulation and transplantation of cells. Also disclosed are high throughput methods for the characterizing the biocompatibility and physiochemical properties of modified alginate polymers.

Abstract: The present invention relates to a pharmaceutical dosage form delivering an immediate release profile containing the active substance 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate.

Abstract: A pharmaceutical composition in form of an aqueous colloid or an aqueous suspension of particles up to a size of 100 ?m comprises or consists of amphiphilic sulfonate or sulfate of a hydrophilic cancer drug having a solubility in water or aqueous body fluid of less than 0.1% by weight. Also disclosed are the particles in powderous form, methods for their production and for the production of the colloid and the courser suspension, a method of treating liver cancer, in particular solid liver cancer tumours, by administration of the pharmaceutical composition, and a method of designing a composition according to the invention.

Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the treatment of of nocturnal snoring. In particular the CBD appears particularly effective in treating nocturnal snoring in children and young adults with epilepsy the disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).

Abstract: Provided is a composition for oral intake, which exhibits improved oral absorbability of curcumin and/or an analog thereof and can be produced conveniently and inexpensively. A complex of curcumin and/or an analog thereof and a water-soluble cellulose derivative is disclosed.

Abstract: The present invention relates to pharmaceutical compositions and methods of manufacturing the same, comprising a eutectic of Cyclobenzaprine HCl and mannitol or Amitriptyline HCl and mannitol.

Abstract: The present invention provides for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.

Abstract: Hydroxy aliphatic substituted phenyl aminoalkyl ether compounds of formula (I), and compositions thereof, are useful as a medicament in the treatment of nervous system diseases and/or the treatment of developmental, behavioral and/or mental disorders associated with cognitive deficits.

Abstract: The present invention is directed towards a medicament comprising a capsaicinoid possessing antiviral activity and useful in the treatment of viral infections and in the treatment of HIV/AIDS. The medicament also possesses neuroplasticity-enhancing activity and is useful in the treatment of stress and other psychological conditions. Further, the medicament possesses anti-inflammatory activity and is useful in the treatment of arthritis. The medicament has also been shown to possess antibacterial activity.

Abstract: Sustained release compositions of sotalol, or a pharmaceutically acceptable salt thereof, are provided. In certain examples, sotalol, or a pharmaceutically acceptable salt thereof, may be administered in an effective amount to provide a therapeutic effect to a patient, such as, for example, a patient suffering from a cardiac disorder. In some examples, sotalol combined with a sustained release system may be administered to provide a sustained release of sotalol for a desired period, e.g., at least about 24 hours.

Abstract: A method of treating a cellular injury in a subject comprising administering to a subject in need thereof, a therapeutically effective amount of a compound of formula I: wherein at least one of R1-R8 is a sulfonic acid, a carboxylic acid, a phosphonic acid, a pharmaceutically acceptable salt of a sulfonic acid, a pharmaceutically acceptable salt of a carboxylic acid, a pharmaceutically acceptable salt of a phosphonic acid, a sulfonate ester, a carboxylate acid ester, or a phosphonate ester; and the remaining R1-R8 are each independently selected from hydrogen, halo, hydroxyl, nitro, nitroso, amino, substituted amino, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, alkoxy, substituted alkoy, alkenyloxy, substituted alkenyloxy, alkynyloxy, substituted alkynyloxy, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, cycloalkynyl, substituted cycloalkynyl, cycloalkyloxy, substituted cycloalkyloxy, heterocyclyl, substituted heterocyclyl, heterocycl

Abstract: The present invention relates to glycolic acid or a pharmaceutically acceptable salt or ester thereof for use in the treatment or prevention of male infertility. The present invention also relates to an ex vivo method for increasing the mobility of spermatozoa comprising contacting glycolic acid or a pharmaceutically acceptable salt or ester thereof with spermatozoa.

Abstract: Cyclopentene carboxylic acid-related compounds as GABA-AT inhibitors for treatment of various addictions, disorders and disease states.

Abstract: Disclosed is a pregabalin sustained-release preparation, wherein the sustained-release tablet contains a pharmaceutically active ingredient containing pregabalin or a salt or hydrate thereof, a gel framework material containing alginic acid, and a swellable material containing polyoxyethylene.